$TRDA News
Last published 3d ago
- 3d agoTRDAGuggenheim 3rd Annual Healthcare Innovation Conference - ENTRADA THERAPEUTICS INCEarnings Call TranscriptsJoining me for the first afternoon session is Deepal Doshi, CEO of Entorado Therapeutics. Deepal, thanks so much. Thanks, Devjit. So, you know, for folks who might be new to your Entorada story, could you give us a very
- 1w agoTRDAEntrada Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoTRDAEntrada Therapeutics Reports Third Quarter 2026 Financial ResultsGlobeNewswire-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- -- Company on track to report ELEVATE-44-201 Cohort 2 data in Q1 2027 – --
- 3w agoTRDAEntrada Therapeutics Appoints Linea Aspesi as Chief People OfficerGlobeNewswireBOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Linea Aspesi as Chief People Officer. "Linea has a proven track record of scaling
- 4w agoTRDAEntrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45GlobeNewswire-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg -- -- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate
- 4w agoTRDAIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyGlobeNewswire-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) --
- 2mo agoTRDAEntrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramGlobeNewswire-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE
- 2mo agoTRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units ("RSUs") and options to purchase
- 3mo agoTRDAEntrada Therapeutics Reports Second Quarter 2026 Financial ResultsGlobeNewswire-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201
- 5mo agoTRDAGoldman Sachs 47th Annual Global Healthcare Conference - Goldman SachsEarnings Call TranscriptsGood morning. Thank you for joining us. I'm Paul Choi, and I cover the mid-cap biotech sector here at Goldman Sachs. Joining us here at the Goldman Sach global healthcare conference is Entrata. Before we begin, I'm requi
- 5mo agoTRDAIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 StudyGlobeNewswire-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) --
- 5mo agoTRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units ("RSUs") to three newly-hired non-executive
- 6mo agoTRDAEntrada Therapeutics Reports First Quarter 2026 Financial ResultsGlobeNewswire-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1
- 6mo agoTRDAEntrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 StudyGlobeNewswire-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal
- 6mo agoTRDAEntrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026GlobeNewswireBOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2
- 8mo agoTRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units ("RSUs") to two newly-hired non-executive
- 8mo agoTRDAEntrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire– Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 – – Company on track to report ELEVATE-45-201 data from Cohort 1 in mid-2026 – – Independent Data Monitoring
- 8mo agoTRDAIndependent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyGlobeNewswire-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb.
- 9mo agoTRDAEntrada Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit
- 11mo agoTRDAEntrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan
- 1y agoTRDAEntrada Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 --
- 1y agoTRDAEntrada Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in
- 1y agoTRDAEntrada Therapeutics Announces Recipients of Third Annual DREAMS Grant ProgramGlobeNewswire-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in
- 1y agoTRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 54,360 restricted stock units ("RSUs") and options to purchase 38,850 shares
- 1y agoTRDAEntrada Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswire-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites
- 1y agoBIIBTRDAEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsGlobeNewswireBOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan
- 1y agoTRDAEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 23,820 restricted stock units ("RSUs") to six newly-hired non-executive
- 1y agoTRDAEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingGlobeNewswire– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025
- 1y agoTRDAEntrada Therapeutics Reports First Quarter 2025 Financial ResultsGlobeNewswire– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company
- 1y agoTRDAEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingGlobeNewswire– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne
- 1y agoTRDAEntrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for
- 1y agoTRDAEntrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44GlobeNewswire– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and
- 1y agoTRDAEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular DystrophyGlobeNewswire– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025
- 1y agoAZTATRDAAzenta Announces the Election of Dipal Doshi to its Board of DirectorsPR NewswireAzenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader...
- 1y agoTRDAEntrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that
- 2y agoTRDAEntrada Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory
- 2y agoTRDAEntrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle SocietyGlobeNewswire– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial
- 2y agoTRDAEntrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and DevelopmentGlobeNewswireBOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape
- 2y agoTRDAāshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of DirectorsBusiness Wireāshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of
- 2y agoTRDAEntrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant ProgramGlobeNewswire- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne
- 2y agoTRDAEntrada Therapeutics Reports Second Quarter 2024 Financial ResultsGlobeNewswire– Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent plasma and muscle concentration, and exon skipping – – Planning underway for separate global Phase 2 clinical
- 2y agoTRDAEntrada Therapeutics Announces $100 Million Registered Direct OfferingGlobeNewswireBOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that
- 2y agoTRDAEntrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular DystrophyGlobeNewswire– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or
- 2y agoTRDAEntrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswireBOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that
- 2y agoTRDAEntrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewswireBOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that
- 2y agoTRDAEntrada Therapeutics Reports First Quarter 2024 Financial ResultsGlobeNewswire– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment
- 2y agoTRDAEntrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of
- 2y agoTRDAEntrada Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape
- 2y agoTRDAEntrada Therapeutics Promotes Nathan J. Dowden to PresidentGlobeNewswire- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada's operational growth - BOSTON, Jan. 03, 2024 (GLOBE
- 2y agoTRDAEntrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular DystrophyGlobeNewswire– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – –